Owner Scorecard


← All companies ← CNS Manual CNX → ← CBIO Pharmaceuticals COLL →

CNTB, Connect Biopharma Holdings Limited

Pharmaceuticals consumer brand UnprofitableNet current asset value

Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease.

Significant Unmet Need and Market Opportunity in COPD COPD is a group of certain types of irreversible inflammatory diseases, including emphysema and chronic bronchitis, that obstruct the lungs and airways and make it difficult to breathe.

Latest annual: FY2025 10-K
CNTB · Connect Biopharma Holdings Limited
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$64K
−99.8% YoY
Vital signs · TTM, with 3-yr average
Revenue $3M 3-yr avg $9M
Free cash flow margin −2053% 3-yr avg −40391%

Next report By 11/13 · the 10-Q for the quarter ended late September · due within 45 days of period end · has filed ~43 days after · the wire records it on arrival

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn. Net current asset value. Current assets alone exceed every liability combined, and the surplus is most of the balance sheet: the shape Graham called a net-net.
What moves the needle
The pipeline against the patent cliff, and pricing. What decides it: whether new drugs replace those losing exclusivity, the odds in the clinical pipeline, and how durable pricing stays against payers and generics. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

Most recent quarterly filing 10-Q filed Aug 12, 2026 Source at SEC EDGAR →

Revenue up 5666.7% year over year

figures computed from the filing's XBRL

The record, 2023–2025

realized figures from each filing · older years to the left
2023’232024’242025’25TTMTTMJun 2026
Income statement
$0$26M$64K$3MRevenueRevenue
74%n/m666%SG&A / revenueSG&A/rev
112%n/mn/mR&D / revenueR&D/rev
($69M)($22M)($58M)($70M)Operating incomeOp. inc.
−86.2%n/mn/mOperating marginOp. mgn
($62M)($15M)($55M)Pretax incomePretax
($62M)($16M)($55M)($69M)Net incomeNet inc.
Cash flow & returns
($48M)($24M)($51M)($61M)Operating cash flowOp. cash
$720K$660K$704K$685KDepreciation & amortizationD&A
$8M($15M)($156K)$3MWorking capital & otherWC & other
$81K$750K$434K$50KCapexCapex
2.9%678.1%1.7%Capex / revenueCapex/rev
($48M)($24M)($52M)($61M)Owner earningsOwner earn.
−93.6%n/mn/mOwner earnings marginOE mgn
($48M)($24M)($52M)($61M)Free cash flowFCF
−93.6%n/mn/mFree cash flow marginFCF mgn
$75M($3M)$10MInvesting cash flowInv. cash
$45K$227K$1MFinancing cash flowFin. cash
($568K)($595K)$408KExchange-rate effectFX
$27M($27M)($40M)Change in cashΔ cash
-127%-1262%ROICROIC
-61%-17%-132%-257%Return on equityROE
−61%−17%−132%−257%Retained to equityRetained/eq
Balance sheet
$118M$94M$44M$31MCash & investmentsCash+inv
$0$789K$13K$3MReceivablesReceiv.
$2M$342K$2M$2MAccounts payablePayables
($2M)$447K($2M)$920KOperating working capitalOper. WC
$123M$97M$51M$39MCurrent assetsCur. assets
$25M$8M$14M$16MCurrent liabilitiesCur. liab.
4.8×11.5×3.7×2.4×Current ratioCurr. ratio
$4M$4M$4MNet PP&ENet PP&E
$127M$101M$56M$43MTotal assetsAssets
($118M)($94M)($44M)($31M)Net debt / (cash)Net debt
$26M$9M$14MTotal liabilitiesTotal liab.
$101M$92M$42M$27MShareholders’ equityEquity
25.8%n/m145.4%Stock comp / revenueSBC/rev
Per share
55.1M55.2M55.7M59.7MShares out (diluted)Shares
$0.00$0.47$0.00$0.05Revenue / shareRev/sh
$-1.13$-0.28$-1.00$-1.16EPS (diluted)EPS
$-0.87$-0.44$-0.93$-1.02Owner earnings / shareOE/sh
$-0.87$-0.44$-0.93$-1.02Free cash flow / shareFCF/sh
$0.00$0.01$0.01$0.00Cap. spending / shareCapex/sh
$1.84$1.67$0.75$0.45Book value / shareBVPS

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business turned a $55M loss into ($52M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

FY2025FY2024FY2023
Reported net income($55M)($16M)($62M)
Depreciation & amortizationnon-cash charge added back+$704K+$660K+$720K
Stock-based compensationreal costnon-cash, but a real cost+$4M+$7M+$5M
Working capital & othertiming of cash in and out, other non-cash items−$156K−$15M+$8M
Cash from operations($51M)($24M)($48M)
Capital expenditurecash put back in to keep running and to grow−$434K−$750K−$81K
Owner earnings($52M)($24M)($48M)
Owner-earnings marginowner earnings ÷ revenue-80687%-94%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $4M), owner earnings is nearer ($55M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • No meaningful interest burden
    Little or no interest expense reported
    What this means

    Little or no interest expense reported, the business isn't leaning on lenders to operate.

  • Net cash, debt-free
    Cash $38M + ST investments $6M − debt $0
    What this means

    Cash and short-term investments exceed every dollar of debt by $44M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Not enough data
    Industry peers: median -88%
    What this means

    The filing data didn't include the inputs for this check.

  • Consumes cash
    Owner earnings ($52M) = operating cash ($51M) − maintenance capex $434K
    Industry peers: median -186%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -80688% of revenue this year. Treating stock comp as the real expense it is (less $4M of SBC) leaves ($55M).

  • Loss, and burning cash
    Net income ($55M) · cash from operations ($51M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 0.62×
    Harvesting
    Capex $434K ÷ depreciation & amortization as filed $704K
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

The promise and the pay packet

  • Is the buyback buying ownership, or mopping up? 5821.9%
    The count is flat
    Stock compensation $4M (fiscal 2025), 5821.9% of revenue · no repurchases · diluted shares +1.1% since 2023
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 1 of 2 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $64K
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 3.74×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.71/share (latest year $-0.88), the averaged base the calculator's gate runs on, and book value is $0.67/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$39M
  • Cash & short-term investments$31M
  • Receivables$3M
  • Other current assets$4M
Current liabilities$16M
  • Accounts payable$2M
  • Other current liabilities$14M
Current ratio2.37×all current assets ÷ what's due · Graham looked for 2×
Quick ratioinventory untagged this quarter, so withheld rather than shown equal to the current ratio
Cash ratio1.93×strictest: cash alone against what's due
Working capital$22Mthe cushion left after near-term bills
Cash runway0.5 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Revenue, latest quarter vs. a year ago+5666.7%the freshest read on whether the business is still growing
Current ratio, recent quarters11.5× → 2.4×
Deeper floors
Tangible book value$27Mequity stripped of goodwill & intangibles
Net current asset value$22MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$596K$596K of it operating leases

From the company's latest filing.

Management, ownership & pay

From the proxy: how much of the business the people running it own, and how they are paid.

  • Stock-based compensation$4M

    The slice of the business handed to employees in shares in fiscal 2025, 5821.9% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
FBIOPFortress Biotech, Inc.$63M68%-271.4%-372%-240%
XOMAXOMA Royalty Corporation$52M-21.1%-16%-131%
VSTMVerastem Inc.$31M-452.5%-78%-283%3y
IVAInventiva S.A.$16M-468.9%3y-396%
IRDOpus Genetics Inc.$14M-139.8%-506%2y-121%1y
CNTBConnect Biopharma Holdings Limited$64K-86.2%1y-695%2y-94%1y
AVTXAvalo Therapeutics Inc.$59K63%4y-223.2%4y-97%-101%4y
IFRXInflaRx N.V.as filed: €29K-52%3y
Group median-223.2%-235%-126%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Connect Biopharma Holdings Limited is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−2053%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Connect Biopharma Holdings Limited (CNTB), the owner's record," https://ownerscorecard.com/c/CNTB, data as of 2026-08-17.

Manual order: ← CNS its page in the Manual CNX →

Industry order: ← CBIO the Pharmaceuticals chapter COLL →